nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Allometric or Lean Body Mass Scaling of Propofol Pharmacokinetics
|
Coetzee, Johan Francois |
|
2012 |
|
3 |
p. 137-145 |
artikel |
2 |
Allometric or Lean Body Mass Scaling of Propofol Pharmacokinetics
|
Coetzee, Johan Francois |
|
2012 |
|
3 |
p. 137-145 |
artikel |
3 |
Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
|
Calvier, Elisa A. M. |
|
2016 |
|
3 |
p. 273-285 |
artikel |
4 |
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review
|
Rao, Prakruti S. |
|
|
|
3 |
p. 375-398 |
artikel |
5 |
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses
|
Glatard, Anaïs |
|
|
|
3 |
p. 371-382 |
artikel |
6 |
A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor
|
Song, Ling |
|
|
|
3 |
p. 505-518 |
artikel |
7 |
An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions
|
Joshi, Shashank |
|
|
|
3 |
p. 349-357 |
artikel |
8 |
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects
|
Sadaf, Alina |
|
|
|
3 |
p. 357-365 |
artikel |
9 |
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
|
Tate, Sonya C. |
|
2017 |
|
3 |
p. 335-344 |
artikel |
10 |
A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation
|
Ding, Junjie |
|
2014 |
|
3 |
p. 305-317 |
artikel |
11 |
Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment
|
Nakai, Kiyohiko |
|
2014 |
|
3 |
p. 295-304 |
artikel |
12 |
A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans
|
Kiang, Tony K. L. |
|
2015 |
|
3 |
p. 313-358 |
artikel |
13 |
Are Population Pharmacokinetic and/ or Pharmacodynamic Models Adequately Evaluated?
|
Brendel, Karl |
|
|
|
3 |
p. 221-234 |
artikel |
14 |
A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations
|
Prybylski, John P. |
|
2016 |
|
3 |
p. 263-272 |
artikel |
15 |
Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”
|
Jelliffe, Roger W. |
|
2016 |
|
3 |
p. 313-316 |
artikel |
16 |
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates
|
Alrahahleh, Dua’a |
|
|
|
3 |
p. 367-380 |
artikel |
17 |
Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union
|
Kuribayashi, Ryosuke |
|
2016 |
|
3 |
p. 225-233 |
artikel |
18 |
Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
|
Gomez-Mantilla, Jose David |
|
|
|
3 |
p. 457-480 |
artikel |
19 |
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
|
Wind, Sven |
|
2016 |
|
3 |
p. 235-250 |
artikel |
20 |
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin
|
Molina, Kyle C. |
|
|
|
3 |
p. 363-374 |
artikel |
21 |
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
|
Wasmann, Roeland E. |
|
2017 |
|
3 |
p. 267-286 |
artikel |
22 |
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
|
Pang, Yinuo |
|
|
|
3 |
p. 311-326 |
artikel |
23 |
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
|
Czock, David |
|
|
|
3 |
p. 347-362 |
artikel |
24 |
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
|
Müller, Thomas |
|
2016 |
|
3 |
p. 251-261 |
artikel |
25 |
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
|
Campagne, Olivia |
|
|
|
3 |
p. 283-303 |
artikel |
26 |
Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
|
He, Yan-Ling |
|
2012 |
|
3 |
p. 147-162 |
artikel |
27 |
Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
|
He, Yan-Ling |
|
2012 |
|
3 |
p. 147-162 |
artikel |
28 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
|
Hey, John A. |
|
2017 |
|
3 |
p. 315-333 |
artikel |
29 |
Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors
|
Song, Jessica C. |
|
|
|
3 |
p. 207-224 |
artikel |
30 |
Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT1B/1D Receptor Agonist for the Treatment of Migraine
|
McEnroe, Janet D. |
|
|
|
3 |
p. 237-246 |
artikel |
31 |
Clinical Pharmacokinetics of Daptomycin
|
Gregoire, Nicolas |
|
|
|
3 |
p. 271-281 |
artikel |
32 |
Clinical Pharmacokinetics of Drugs in Patients with Heart Failure
|
Ogawa, Ryuichi |
|
2013 |
|
3 |
p. 169-185 |
artikel |
33 |
Clinical Pharmacokinetics of Nisoldipine Coat-Core
|
Heinig, Roland |
|
|
|
3 |
p. 191-208 |
artikel |
34 |
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
|
Shebley, Mohamad |
|
|
|
3 |
p. 297-309 |
artikel |
35 |
Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions
|
Van der Linden, Lorenz |
|
|
|
3 |
p. 395-396 |
artikel |
36 |
Comment on: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools”
|
Proost, Johannes H. |
|
2016 |
|
3 |
p. 311-312 |
artikel |
37 |
Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
|
Grant, Marshall |
|
|
|
3 |
p. 413-422 |
artikel |
38 |
Correction to: Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions
|
Willemin, Marie-Emilie |
|
|
|
3 |
p. 463 |
artikel |
39 |
Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review
|
Ziesenitz, Victoria C. |
|
2017 |
|
3 |
p. 393-417 |
artikel |
40 |
Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
|
Hermann, Robert |
|
2018 |
|
3 |
p. 401 |
artikel |
41 |
Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study
|
Alexopoulos, Dimitrios |
|
2015 |
|
3 |
p. 359-367 |
artikel |
42 |
Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study
|
Tarral, Antoine |
|
|
|
3 |
p. 481-491 |
artikel |
43 |
Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients
|
Yu, Huixin |
|
2016 |
|
3 |
p. 293-303 |
artikel |
44 |
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
|
Badri, Prajakta S. |
|
2015 |
|
3 |
p. 275-295 |
artikel |
45 |
Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection
|
Marzolini, Catia |
|
|
|
3 |
p. 339-346 |
artikel |
46 |
Drug Transporters in the Central Nervous System
|
Stieger, Bruno |
|
2015 |
|
3 |
p. 225-242 |
artikel |
47 |
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
|
Gardin, Anne |
|
2018 |
|
3 |
p. 349-361 |
artikel |
48 |
Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study
|
Horsmans, Yves |
|
2017 |
|
3 |
p. 345-354 |
artikel |
49 |
Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis
|
Terranova, Nadia |
|
2018 |
|
3 |
p. 325-333 |
artikel |
50 |
Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study
|
Kida, Keisuke |
|
2014 |
|
3 |
p. 273-284 |
artikel |
51 |
Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation
|
Schoretsanitis, Georgios |
|
|
|
3 |
p. 329-335 |
artikel |
52 |
Erratum to: Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer
|
Hutson, Paul R. |
|
2016 |
|
3 |
p. 407 |
artikel |
53 |
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
|
Kuilenburg, André B. P. van |
|
2012 |
|
3 |
p. 163-174 |
artikel |
54 |
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
|
Kuilenburg, André B. P. van |
|
2012 |
|
3 |
p. 163-174 |
artikel |
55 |
Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus
|
Nader, Ahmed |
|
|
|
3 |
p. 335-347 |
artikel |
56 |
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
|
van den Berg, Paul |
|
|
|
3 |
p. 439-450 |
artikel |
57 |
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
|
Goulooze, Sebastiaan Camiel |
|
|
|
3 |
p. 451-462 |
artikel |
58 |
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight
|
Rekić, Dinko |
|
|
|
3 |
p. 319-328 |
artikel |
59 |
How Accurate and Precise Are Limited Sampling Strategies in Estimating Exposure to Mycophenolic Acid in People with Autoimmune Disease?
|
Abd Rahman, Azrin N. |
|
2013 |
|
3 |
p. 227-245 |
artikel |
60 |
Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients
|
Farag, Sheima |
|
2016 |
|
3 |
p. 287-292 |
artikel |
61 |
Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review
|
Edwina, Angela Elma |
|
|
|
3 |
p. 351-373 |
artikel |
62 |
Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome
|
Liu, Zhiyan |
|
|
|
3 |
p. 435-447 |
artikel |
63 |
Interethnic Differences in Pharmacokinetics of Antibacterials
|
Tsai, Danny |
|
2014 |
|
3 |
p. 243-260 |
artikel |
64 |
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials
|
Ji, Yan |
|
|
|
3 |
p. 493-504 |
artikel |
65 |
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy
|
Bouazza, Naïm |
|
|
|
3 |
p. 333-342 |
artikel |
66 |
Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions
|
Yeung, Cindy H. T. |
|
|
|
3 |
p. 317-332 |
artikel |
67 |
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
|
Zhou, Shufeng |
|
|
|
3 |
p. 279-304 |
artikel |
68 |
Modelling the Sitagliptin Effect on Dipeptidyl Peptidase-4 Activity in Adults with Haematological Malignancies After Umbilical Cord Blood Haematopoietic Cell Transplantation
|
Vélez de Mendizábal, Nieves |
|
2013 |
|
3 |
p. 247-259 |
artikel |
69 |
Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
|
Gao, Yanhua |
|
2018 |
|
3 |
p. 389-399 |
artikel |
70 |
Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
|
Huh, Yeamin |
|
|
|
3 |
p. 381-394 |
artikel |
71 |
Nitrite: On the Journey from Toxin to Therapy
|
Blood, Arlin B. |
|
2015 |
|
3 |
p. 221-223 |
artikel |
72 |
Ocular Pharmacokinetics and Safety of Ciclosporin, a Novel Topical Treatment for Dry Eye
|
Tang-Liu, Diane D.-S. |
|
|
|
3 |
p. 247-261 |
artikel |
73 |
Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia
|
Shi, Jun |
|
|
|
3 |
p. 317-329 |
artikel |
74 |
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers
|
Boettcher, Michael |
|
|
|
3 |
p. 337-351 |
artikel |
75 |
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
|
Scheen, André J. |
|
2014 |
|
3 |
p. 213-225 |
artikel |
76 |
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
|
Badri, Prajakta |
|
|
|
3 |
p. 365-378 |
artikel |
77 |
Pharmacokinetic Considerations in the Treatment of Tuberculosis in Patients with Renal Failure
|
Launay-Vacher, Vincent |
|
|
|
3 |
p. 221-235 |
artikel |
78 |
Pharmacokinetic/Pharmacodynamic Evaluation of Antimicrobial Treatments of Orofacial Odontogenic Infections
|
Isla, Arantxa |
|
|
|
3 |
p. 305-316 |
artikel |
79 |
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
|
Courlet, Perrine |
|
|
|
3 |
p. 379-390 |
artikel |
80 |
Pharmacokinetic Profile of Artemisinin Derivatives and Companion Drugs Used in Artemisinin-Based Combination Therapies for the Treatment of Plasmodium falciparum Malaria in Children
|
Pawluk, Shane A. |
|
2012 |
|
3 |
p. 153-167 |
artikel |
81 |
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
|
Jacus, Megan O. |
|
2015 |
|
3 |
p. 297-311 |
artikel |
82 |
Pharmacokinetics and Pharmacodynamics of Temocillin
|
Alexandre, Kevin |
|
2017 |
|
3 |
p. 287-296 |
artikel |
83 |
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
|
Galiën, Ruben van der |
|
2018 |
|
3 |
p. 309-323 |
artikel |
84 |
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
|
Deng, Rong |
|
2017 |
|
3 |
p. 367-377 |
artikel |
85 |
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects
|
Rix, Peter J. |
|
2014 |
|
3 |
p. 261-272 |
artikel |
86 |
Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease
|
Coskun, Mehmet |
|
|
|
3 |
p. 257-274 |
artikel |
87 |
Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease
|
Coskun, Mehmet |
|
2015 |
|
3 |
p. 257-274 |
artikel |
88 |
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
|
Odore, Elodie |
|
2015 |
|
3 |
p. 397-405 |
artikel |
89 |
Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
|
Colbers, Angela |
|
2015 |
|
3 |
p. 381-396 |
artikel |
90 |
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions
|
Kanter, Ruben de |
|
2015 |
|
3 |
p. 369-380 |
artikel |
91 |
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly
|
Stader, Felix |
|
|
|
3 |
p. 383-401 |
artikel |
92 |
Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
|
González-Sales, Mario |
|
2014 |
|
3 |
p. 285-294 |
artikel |
93 |
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
|
Fernandez-Teruel, Carlos |
|
2018 |
|
3 |
p. 363-374 |
artikel |
94 |
Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
|
Snelder, Nelleke |
|
|
|
3 |
p. 359-370 |
artikel |
95 |
Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia
|
Hibma, Jennifer |
|
2018 |
|
3 |
p. 335-347 |
artikel |
96 |
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis
|
Yan, Li |
|
|
|
3 |
p. 387-400 |
artikel |
97 |
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
|
Mo, Gary |
|
2017 |
|
3 |
p. 355-365 |
artikel |
98 |
Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation
|
Monchaud, Caroline |
|
2012 |
|
3 |
p. 175-186 |
artikel |
99 |
Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation
|
Monchaud, Caroline |
|
2012 |
|
3 |
p. 175-186 |
artikel |
100 |
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation
|
Chen, Jingcheng |
|
|
|
3 |
p. 303-316 |
artikel |
101 |
Population Pharmacokinetics of Levetiracetam: A Systematic Review
|
Li, Zi-ran |
|
|
|
3 |
p. 305-318 |
artikel |
102 |
Population Pharmacokinetics of Losmapimod in Healthy Subjects and Patients with Rheumatoid Arthritis and Chronic Obstructive Pulmonary Diseases
|
Yang, Shuying |
|
2012 |
|
3 |
p. 187-198 |
artikel |
103 |
Population Pharmacokinetics of Orally Administered Duloxetine in Patients
|
Lobo, Evelyn D. |
|
2009 |
|
3 |
p. 189-197 |
artikel |
104 |
Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
|
Lo, Arthur |
|
|
|
3 |
p. 391-401 |
artikel |
105 |
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
|
Suleiman, Ahmed A. |
|
2018 |
|
3 |
p. 375-387 |
artikel |
106 |
Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients
|
Aulin, L. B. S. |
|
|
|
3 |
p. 353-363 |
artikel |
107 |
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
|
P. Solans, Belén |
|
2017 |
|
3 |
p. 379-392 |
artikel |
108 |
Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors
|
Noetzli, Muriel |
|
2013 |
|
3 |
p. 211-223 |
artikel |
109 |
Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study
|
Wu, Yunjiao |
|
|
|
3 |
p. 401-412 |
artikel |
110 |
Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
|
Montanha, Maiara Camotti |
|
|
|
3 |
p. 375-386 |
artikel |
111 |
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling
|
Mehta, Krina |
|
|
|
3 |
p. 519-532 |
artikel |
112 |
Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study
|
Kloth, Jacqueline S. L. |
|
2013 |
|
3 |
p. 261-269 |
artikel |
113 |
Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
|
Bins, Sander |
|
2016 |
|
3 |
p. 305-310 |
artikel |
114 |
Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure
|
Goutelle, Sylvain |
|
2014 |
|
3 |
p. 319-320 |
artikel |
115 |
Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure: Authors’ Reply
|
Lindh, Jonatan D. |
|
2014 |
|
3 |
p. 321 |
artikel |
116 |
Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure
|
Castellan, Anne-Charlotte |
|
2013 |
|
3 |
p. 199-209 |
artikel |
117 |
Respirable Microspheres for Inhalation
|
Sakagami, Masahiro |
|
|
|
3 |
p. 263-277 |
artikel |
118 |
Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions
|
Azeredo, Francine Johansson |
|
2014 |
|
3 |
p. 205-212 |
artikel |
119 |
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
|
Fan, Yuru |
|
|
|
3 |
p. 293-302 |
artikel |
120 |
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?
|
Davies Forsman, Lina |
|
|
|
3 |
p. 269-278 |
artikel |
121 |
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology
|
Chatelut, Etienne |
|
|
|
3 |
p. 287-296 |
artikel |
122 |
Sex Differences in Pharmacokinetics and Pharmacodynamics
|
Soldin, Offie P. |
|
|
|
3 |
p. 143-157 |
artikel |
123 |
Should the Currently Recommended Twice-Daily Dosing Still be Considered the Most Appropriate Regimen for Treating MRSA Ventilator-Associated Pneumonia with Vancomycin?
|
Pea, Federico |
|
|
|
3 |
p. 147-152 |
artikel |
124 |
Strategies for Increasing Drug Delivery to the Brain
|
Siegal, Tali |
|
|
|
3 |
p. 171-186 |
artikel |
125 |
The Basel Cocktail for Simultaneous Phenotyping of Human Cytochrome P450 Isoforms in Plasma, Saliva and Dried Blood Spots
|
Donzelli, Massimiliano |
|
2013 |
|
3 |
p. 271-282 |
artikel |
126 |
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
|
Hermann, Robert |
|
2018 |
|
3 |
p. 283-297 |
artikel |
127 |
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
|
Hermann, Robert |
|
|
|
3 |
p. 283-297 |
artikel |
128 |
The Clinical Pharmacology of Elotuzumab
|
Passey, Chaitali |
|
2017 |
|
3 |
p. 297-313 |
artikel |
129 |
The Effect of BMI on Pharmacokinetic and Pharmacodynamic Parameters of Insulin Degludec: Results from an Euglycemic Glucose Clamp Study
|
Li, Ting |
|
|
|
3 |
p. 449-456 |
artikel |
130 |
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition
|
Bensalem, Amina |
|
|
|
3 |
p. 423-437 |
artikel |
131 |
The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs
|
Groen, F. |
|
|
|
3 |
p. 399-434 |
artikel |
132 |
Therapeutic Drug Monitoring of Imatinib
|
Gotta, Verena |
|
2012 |
|
3 |
p. 187-201 |
artikel |
133 |
Therapeutic Drug Monitoring of Imatinib
|
Gotta, Verena |
|
2012 |
|
3 |
p. 187-201 |
artikel |
134 |
Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology
|
Groenland, Stefanie L. |
|
2018 |
|
3 |
p. 299-308 |
artikel |
135 |
Thiopurine Treatment in Inflammatory Bowel Disease
|
Teml, Alexander |
|
|
|
3 |
p. 187-208 |
artikel |
136 |
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy
|
Ma, Yi |
|
|
|
3 |
p. 279-291 |
artikel |
137 |
Towards a Model-Based Dose Recommendation for Doxorubicin in Children
|
Völler, Swantje |
|
2016 |
|
3 |
p. 215-223 |
artikel |
138 |
Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care
|
van Borselen, Marjolein D. |
|
|
|
3 |
p. 343-355 |
artikel |
139 |
Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations
|
Hsu, Vicky |
|
2013 |
|
3 |
p. 283-293 |
artikel |
140 |
Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis
|
Kanji, Salmaan |
|
|
|
3 |
p. 327-334 |
artikel |